Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.
You may also be interested in...
China Leadership Changes Signal MSD-Simcere JV Shakeup
With the two top execs at MSD-Simcere jumping ship, there was speculation that the JV could be in trouble, but MSD reiterates its strong commitment to China and the JV as the company hastens its pace in the country to introduce more products.
Despite Global Restructuring Plan, It’s Full Steam Ahead In China For Merck
Days after announcing a global restructuring plan, Merck CEO Ken Frazier visits Beijing to pledge $6 million toward the second phase of C-MAP, a public-private partnership with the Chinese government on HIV/AIDS. Frazier’s trip underscores the continuing importance of China to Merck despite a company-wide plan to cut 8,500 positions and reduce operating costs by $2.5 billion by 2015.
IL-17: Pushing The Limits Of A Drug Target
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.